[go: up one dir, main page]

MX2015017201A - Derivados de pirazolopiridina para uso en el tratamiento del cancer de vejiga. - Google Patents

Derivados de pirazolopiridina para uso en el tratamiento del cancer de vejiga.

Info

Publication number
MX2015017201A
MX2015017201A MX2015017201A MX2015017201A MX2015017201A MX 2015017201 A MX2015017201 A MX 2015017201A MX 2015017201 A MX2015017201 A MX 2015017201A MX 2015017201 A MX2015017201 A MX 2015017201A MX 2015017201 A MX2015017201 A MX 2015017201A
Authority
MX
Mexico
Prior art keywords
treatment
bladder cancer
pyrazolopyridine derivatives
pyrazolopyridine
derivatives
Prior art date
Application number
MX2015017201A
Other languages
English (en)
Inventor
Chantal Alcouffe
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MX2015017201A publication Critical patent/MX2015017201A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se refiere al uso de compuestos correspondientes a la fórmula (I): (ver Fórmula) o una sal farmacéuticamente aceptable de éstos, para preparar un medicamento para el tratamiento del cáncer de vejiga.
MX2015017201A 2013-06-14 2014-06-13 Derivados de pirazolopiridina para uso en el tratamiento del cancer de vejiga. MX2015017201A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1355578 2013-06-14
PCT/EP2014/062456 WO2014198942A1 (en) 2013-06-14 2014-06-13 Pyrazolopyridine derivatives for use in the treatment of bladder cancer

Publications (1)

Publication Number Publication Date
MX2015017201A true MX2015017201A (es) 2016-04-06

Family

ID=48906407

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015017201A MX2015017201A (es) 2013-06-14 2014-06-13 Derivados de pirazolopiridina para uso en el tratamiento del cancer de vejiga.

Country Status (13)

Country Link
US (1) US9572799B2 (es)
EP (1) EP3007694B1 (es)
JP (1) JP2016521721A (es)
KR (1) KR20160021134A (es)
CN (1) CN105283184B (es)
AU (1) AU2014280046B2 (es)
CA (1) CA2915321A1 (es)
EA (1) EA030558B1 (es)
ES (1) ES2691923T3 (es)
MX (1) MX2015017201A (es)
PL (1) PL3007694T3 (es)
TR (1) TR201815333T4 (es)
WO (1) WO2014198942A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
CN107652289B (zh) 2012-06-13 2020-07-21 因塞特控股公司 作为fgfr抑制剂的取代的三环化合物
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
KR102269032B1 (ko) 2013-04-19 2021-06-24 인사이트 홀딩스 코포레이션 Fgfr 저해제로서 이환식 헤테로사이클
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
PE20171514A1 (es) 2015-02-20 2017-10-20 Incyte Corp Heterociclos biciclicos como inhibidores de fgfr
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CN108774224B (zh) * 2018-04-23 2020-10-30 浙江大学 吡唑并[3,4-b]吡啶类化合物及其制备方法和应用
BR112020022373A2 (pt) 2018-05-04 2021-02-02 Incyte Corporation sais de um inibidor de fgfr
SG11202010636VA (en) 2018-05-04 2020-11-27 Incyte Corp Solid forms of an fgfr inhibitor and processes for preparing the same
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
KR102853551B1 (ko) 2019-03-19 2025-09-02 삼성전자주식회사 무선 통신 시스템에서 이중 접속을 위한 단말의 상향 채널 전송 방법 및 장치
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021025543A1 (en) 2019-08-08 2021-02-11 Samsung Electronics Co., Ltd. Method and apparatus for performing dual connectivity for ues in wireless communication system
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021076602A1 (en) 2019-10-14 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JP7720840B2 (ja) 2019-12-04 2025-08-08 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式複素環
CN115151539A (zh) 2019-12-04 2022-10-04 因赛特公司 Fgfr抑制剂的衍生物
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US12065494B2 (en) 2021-04-12 2024-08-20 Incyte Corporation Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent
AR126102A1 (es) 2021-06-09 2023-09-13 Incyte Corp Heterociclos tricíclicos como inhibidores de fgfr
CA3220155A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG171765A1 (en) * 2008-11-20 2011-07-28 Genentech Inc Pyrazolopyridine pi3k inhibitor compounds and methods of use
FR2984325A1 (fr) * 2011-12-14 2013-06-21 Sanofi Sa Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique

Also Published As

Publication number Publication date
TR201815333T4 (tr) 2018-11-21
US20160128989A1 (en) 2016-05-12
PL3007694T3 (pl) 2018-12-31
CN105283184A (zh) 2016-01-27
AU2014280046B2 (en) 2019-07-11
EP3007694B1 (en) 2018-07-18
KR20160021134A (ko) 2016-02-24
AU2014280046A1 (en) 2016-01-07
ES2691923T3 (es) 2018-11-29
EP3007694A1 (en) 2016-04-20
EA201690020A1 (ru) 2016-04-29
US9572799B2 (en) 2017-02-21
WO2014198942A1 (en) 2014-12-18
EA030558B1 (ru) 2018-08-31
CA2915321A1 (en) 2014-12-18
JP2016521721A (ja) 2016-07-25
CN105283184B (zh) 2018-01-26

Similar Documents

Publication Publication Date Title
MX2015017201A (es) Derivados de pirazolopiridina para uso en el tratamiento del cancer de vejiga.
PH12019501321B1 (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3k-delta related disorders
SA515360469B1 (ar) مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها
PH12016501972A1 (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
MA39986A (fr) Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer
MX2015014298A (es) Compuestos de dihidropirido pirimidina como inhibidores de autotaxina.
PH12015501993A1 (en) Pyrazole-amide compound and medicinal uses therefor
NZ704266A (en) Inhibitors of alpha-crystallin aggregation for the treatment for cataract
PH12014501258A1 (en) Pyrazolopyridine derivatives, preparation process therefor and therapeutic use thereof
PH12015501088A1 (en) Dimeric compounds
GB201209587D0 (en) Therapeutic compounds
PH12015502616A1 (en) Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer
PH12018501709A1 (en) Naphthridinedione derivatives
GEAP201914284A (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
SA517381678B1 (ar) مركبات داي هيدرو بيريميدين-2-أون واستخدامها الطبي
PH12015500399A1 (en) Azaindolines
NZ732704A (en) Quinoline carboxamides for use in the treatment of leukemia
ZA201802399B (en) Aminothiolester compounds or pharmaceutically acceptable salts thereof, for use in the treatment of cancer
MX365192B (es) Derivados de bendamustina y compuestos relacionados, y uso medico de los mismos para la terapia de cancer.
MX2017002627A (es) Derivados de polieteres macrociclicos de n-aril-2-amino-4-aril-pir imidina como inhibidores de ftl3 y jak.
TN2015000095A1 (en) Macrolide derivatives, preparation thereof and therapeutic use thereof
PH12014501537A1 (en) Therapeutic use of imidazopyridine derivatives
PH12015502703A1 (en) Pharmaceutical compositions
PH12015500282A1 (en) N-acylhydrazone derivatives for selective t cell inhibitor and anti-lymphoid malignancy drug
MX2017002747A (es) Derivados de polieteres macrociclicos de n-aril-triciclopirimidin- 2-amino como inhibidores de ftl3 y jak.